Fusion Pharmaceuticals (NASDAQ:FUSN) Hits New 12-Month High at $21.56

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $21.56 and last traded at $21.55, with a volume of 390082 shares traded. The stock had previously closed at $21.43.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $21.00 price objective (up from $16.00) on shares of Fusion Pharmaceuticals in a report on Wednesday, March 20th. Truist Financial reaffirmed a “hold” rating and issued a $21.00 price objective (up from $11.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. SVB Leerink reissued a “market perform” rating and issued a $21.00 target price (up previously from $17.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Raymond James reissued a “market perform” rating on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Finally, William Blair lowered Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 19th. Thirteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Fusion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $20.25.

Fusion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.16, a current ratio of 15.01 and a quick ratio of 15.01. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -14.58 and a beta of -0.72. The business’s fifty day moving average price is $17.40 and its 200-day moving average price is $10.80.

Fusion Pharmaceuticals (NASDAQ:FUSN) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative return on equity of 46.59% and a negative net margin of 4,136.55%. On average, research analysts forecast that Fusion Pharmaceuticals Inc. will post -1.46 EPS for the current year.

Institutional Trading of Fusion Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Signaturefd LLC boosted its position in shares of Fusion Pharmaceuticals by 883.0% during the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock valued at $28,000 after acquiring an additional 2,649 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Fusion Pharmaceuticals by 2,064.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock valued at $29,000 after purchasing an additional 2,869 shares in the last quarter. New York State Common Retirement Fund purchased a new position in Fusion Pharmaceuticals in the 4th quarter worth $64,000. China Universal Asset Management Co. Ltd. bought a new stake in Fusion Pharmaceuticals in the fourth quarter worth $80,000. Finally, abrdn plc purchased a new stake in Fusion Pharmaceuticals during the fourth quarter valued at about $209,000. 72.85% of the stock is currently owned by hedge funds and other institutional investors.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.